Hepatitis C, HIV Infections
Conditions
Brief summary
Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin (RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC) together with standard treatment in treating HCV infection in people with HIV-1 and HCV coinfection.
Detailed description
For HIV-1-infected individuals, HCV infection is a leading cause of morbidity and mortality, and the prevalence of HCV infection is higher among those infected with HIV-1. At the time the study was designed, the standard-of-care (SOC) therapy for HCV infection was treatment with both PEG-IFN and RBV. This therapy is 40%-45% effective in patients with HCV infection but is significantly less effective in patients with both HCV and HIV-1 (Shire et al. J Viral Hepat., 2007). The purpose of this study was to evaluate the effectiveness of adding BOC (Kwo et al. Lancet, 2010), an HCV protease inhibitor, to SOC therapy in treating HCV infection (genotype 1) in HCV/HIV-1-coinfected adults. Participants were enrolled into one of two groups based on previous HCV treatment experience. 1. Group A: HCV treatment-naive participants who had never received treatment with PEG-IFN or experimental agents used to treat HCV, with or without RBV (N=170, refer to the note below). 2. Group B: HCV treatment-experienced participants who had received any treatment with standard interferon or with PEG-IFN with or without RBV, provided the last dose of treatment was 90 days or more before study entry (N=140, refer to the note below). Note: The team correspondence with the FDA led to an amendment to close enrollment in December 2013, prior to the target sample sizes of 170 in Group A and 140 in Group B, as the study power could be lowered while still meeting the key study objectives. All participants had to be on stable antiretroviral therapy (ART) for at least 8 weeks prior to study entry using a dual nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone plus one of the following: efavirenz (EFV), raltegravir (RAL), lopinavir (LPV)/ritonavir (RTV) 400/100 mg twice daily, atazanavir (ATV)/RTV, darunavir (DRV)/RTV 600/100 mg twice daily OR must not have received any ART for at least 4 weeks immediately prior to entry. Participation in this study lasted approximately 72 weeks. HCV treatment-naive participants (Group A) were treated with PEG-IFN and RBV for 4 weeks (lead-in). Then BOC was added to the treatment regimen (triple therapy). Cirrhotic participants received 44 weeks of triple therapy. Among non-cirrhotics, the Week 8 HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of double-drug therapy with PEG-IFN/RBV. HCV treatment-experienced participants (Group B) also had a lead-in followed by 32 weeks of triple therapy and 12 weeks of PEG-IFN/RBV double therapy if non-cirrhotic, or by 44 weeks of triple therapy if cirrhotic. Treatment was to be discontinued due to HCV virologic failure if: 1. HCV RNA ≥100 IU/mL at Week 12, 2. detectable HCV RNA at Week 24, or 3. confirmed HCV RNA \>1000 IU/mL any time after Week 12. Undetectable HCV RNA was defined as below the lower limit of quantification (LLOQ) and target not detected (TND) by Roche COBAS® TaqMan® HCV Test v2.0. Study visits were scheduled at screening and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24 and 28 for both study groups. Group A participants who completed treatment at Week 28 had further study visits at Weeks 40, 52, 60, and 72. Participants who were prescribed 48-weeks of therapy (Group A and Group B) had further study visits at Weeks 32, 36, 40, 44, 48, 60, and 72. At each visit, a physical examination and blood collection were conducted. Participants also completed an HCV treatment adherence questionnaire. Select visits included urine collection and pregnancy testing (for women of reproductive potential). Plasma, serum, and peripheral blood mononuclear cells (PBMCs) were be stored for use in future studies. After experiencing HCV virologic failure as defined above or premature treatment discontinuation due to safety or other reasons, participants were followed on a separate schedule of events with visits every 12 weeks from Week 24 to 72. The evaluations at these follow-up visits were limited to safety evaluations and stored plasma/serum sample collection. The A5294 study consisted of single-arm evaluations to assess the efficacy of BOC added to PEG-IFN/RBV in the two study populations: 1. HCV treatment-naive participants (Group A) 2. HCV treatment-experienced participants (Group B). The two study populations were addressed together in this single trial - rather than in two separate trials - mainly for administrative efficiency. The analyses were conducted separately for each Study Group. The study was not designed for comparison. The pooled summaries for Baseline Characteristics provided in the Results Section in this record were prepared solely for the ClinicalTrials.gov results submission.
Interventions
DRUGPegylated-Interferon Alfa 2b (PEG-IFN)
1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
DRUGRibavirin (RBV)
800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
DRUGBoceprevir (BOC)
800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(Groups A and B): * Men and women 18 years of age or older * Presence of chronic HCV infection, defined by presence of plasma or serum HCV RNA in a participant with HCV antibody for at least 180 days, two documented HCV RNA positive results greater than 180 days apart, or positive HCV RNA with biopsy demonstrating chronic hepatitis. More information on this criterion can be found in the protocol. * Serum or plasma HCV RNA level 10,000 IU/mL or greater obtained within 42 days prior to study entry. * Screening HCV genotype 1 performed within 6 months prior to study entry. * Liver biopsy or HCV FibroSURE™ test within 104 weeks prior to study entry with interpretation consistent with chronic HCV infection. If a liver biopsy HCV FibroSURE™ test had not been performed within 104 weeks prior to study entry, then either a biopsy or HCV FibroSURE™ test must have been obtained prior to enrollment. The cut-off value for the FibroSURE™ test was 0.74, where greater than 0.74 was interpreted as cirrhosis. More information on this criterion can be found in the protocol. * Alpha feto protein (AFP) levels less than 50. If 50 or greater, they must have had a liver imaging study (e.g., ultrasound, computed tomography \[CT\] scan, magnetic resonance imaging \[MRI\] showing no evidence of hepatocellular carcinoma. * HIV-1 infection. More information on this criterion can be found in the protocol. * Currently not on any antiretroviral therapy (ART) for at least 4 weeks immediately prior to entry or on stable ART for at least 8 weeks prior to study entry using a dual NRTI backbone PLUS one of the following: EFV, RAL, LPV/RTV 400/100 mg twice daily, ATV/RTV, DRV/RTV 600/100 mg twice daily. Breaks in therapy for a maximum of 14 days were allowed. Dose modifications or changes in drugs during the 8 weeks prior to study entry were permitted unless the change in drug was due to treatment failure. More information on this criterion can be found in the protocol. * CD4+ T-cell count greater than 200 cells/mm\^3 obtained within 42 days prior to study entry. * For participants on ART, screening plasma HIV-1 RNA less than 50 copies/mL obtained within 42 days prior to study entry. For participants not on ART, plasma HIV-1 RNA less than 50,000 copies/mL obtained within 42 days prior to study entry. * The following laboratory values within 42 days prior to entry: * Absolute neutrophil count (ANC) 1000/mm\^3 or greater, * Hemoglobin greater than 12 g/dL for men and greater than 11 g/dL for women, * Platelet count greater than 80,000 per mm\^3, * Creatinine less than 1.5 mg/dL, * Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT), alkaline phosphatase (ALT)/serum glutamic pyruvic transaminaseless (SGPT) less than or equal to 10 x the upper limit of normal (ULN), * Direct bilirubin less than 1.5 mg/dL, * International normalized ratio (INR) less than 1.5, * Serum lipase less than or equal to 1.5 x ULN, * Thyroid stimulating hormone (TSH) within normal range, unless accompanied by thyroid profile consistent with normal thyroid function. * For female participants of reproductive potential, a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL performed within 42 days prior to study entry. More information on this criterion can be found in the protocol. * All participants must have agreed not to participate in a conception process (e.g., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization). * When participating in sexual activity that could lead to pregnancy, participants must have agreed to use at least two reliable methods of contraception simultaneously while receiving protocol-specified medications, and for 6 months after stopping the medications. Such methods include: * Condoms (male or female) with a spermicidal agent, * Diaphragm or cervical cap with spermicide, * Intrauterine device (IUD), * Tubal ligation. More information on this criterion can be found in the protocol. * Participants not of reproductive potential were eligible without requiring the use of contraceptives. More information on this criterion can be found in the protocol. * Ability and willingness of participant to provide written informed consent.
Exclusion criteria
(Groups A and B): * Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation. * Evidence of decompensated liver disease manifested by the presence of or history of ascites, variceal bleeding, or hepatic encephalopathy. If hepatic cirrhosis was determined by liver biopsy (Stage 4 Metavir or Stage 5, 6 Ishak) or by imaging, then participants had to be no more than Child-Pugh Class A and have a Child-Pugh-Turcotte (CPT) score of 6 or less. More information on this criterion can be found in the protocol. * Other known causes of significant liver disease including chronic or acute hepatitis B, acute hepatitis A, hemochromatosis, or homozygote alpha-1 antitrypsin deficiency. * Infection with any HCV genotype other than genotype 1, or mixed genotype infection. * Uncontrolled or active depression or other psychiatric disorder such as untreated. Grade 3 psychiatric disorder or Grade 3 disorder not amenable to medical intervention that in the opinion of the site investigator might have precluded tolerability or safety of study requirements. Individuals with suicidal ideation or history of a suicidal attempt in the last 5 years prior to enrollment were excluded. * History of uncontrolled seizure disorders. * Serious illness including malignancy, active coronary artery disease within 24 weeks prior to study entry, or other chronic medical conditions that in the opinion of the site investigator may have precluded completion of the protocol. * Presence of active or acute AIDS-defining opportunistic infections within 12 weeks prior to study entry. More information on this criterion can be found in the protocol. * History of hemoglobinopathy (e.g., thalassemia) or any other cause of or tendency to hemolysis. * History of major organ transplantation with an existing functional graft. * History of autoimmune processes including Crohn's disease, ulcerative colitis, severe psoriasis, or rheumatoid arthritis that may be exacerbated by IFN use. * Breastfeeding. * Male participants with pregnant sexual partner. * Use of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days prior to study entry. * Use of systemic corticosteroids, lovastatin, simvastatin, interferon gamma, tumor necrosis factor(TNF)-alpha inhibitors, rifampin, rifabutin, pyrazinamide, isoniazid, ganciclovir or hydroxyurea within 14 days prior to study entry. * Previous use of any HCV protease or polymerase inhibitor. * Active drug or alcohol use or dependence that, in the opinion of the site investigator, would have interfered with adherence to study requirements. * Serious illness requiring systemic treatment and/or hospitalization within 42 days prior to entry.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) | 24 weeks after treatment discontinuation | SVR24 was defined as undetectable HCV RNA (below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0) at 24 weeks after treatment discontinuation. Participants without HCV RNA for SVR24 determination were considered not to have achieved SVR24. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12) | 12 weeks after treatment discontinuation | SVR12 was defined as undetectable HCV RNA (below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0) at 12 weeks after treatment discontinuation. Participants without HCV RNA for SVR12 determination were considered not to have achieved SVR12. |
| Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | Entry and weeks (W) 4, 8, 12, 24, 28, 40, 48, 52, 60, 72 | HIV-1 RNA testing was performed with Abbott RealTime HIV-1 assay (LLOQ=40 copies/mL) or with Roche COBAS AmpliPrep/Taqman HIV-1 assay (LLOQ=20 copies/mL). |
| CD4+ T-Cell Count (CD4) Change From Baseline | Entry and weeks (W) 8, 12, 24, 28, 40, 48, 52, 60, 72 | Change in CD4 T-cell count was calculated as value at the post entry visit minus the value at entry. |
| Percentage of Participants With Grade 3 or Higher Adverse Events (AEs) | From study treatment dispensation to Week 72 | Number of participants who experienced an AE (sign or symptom or laboratory abnormality) of Grade 3 or higher at any time after baseline while on study. The AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening. |
| Number of Participants With Undetectable HCV RNA at Week 16, 20, 24 and 28 Study Visits | Weeks (W) 16, 20, 24, and 28 | Undetectable HCV RNA was defined as below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0. This outcome measure was intended for a potential interim analysis when study data up to Week 28 were complete. However, this interim analysis was not conducted. |
| Number of Participants With Grade 2 or Higher Signs and Symptoms and Laboratory Abnormalities and Other Serious AEs | From study treatment dispensation to Week 28 | This outcome measure was intended for a potential interim analysis when study data up to Week 28 were complete. However, this interim analysis was not conducted. Refer to Outcome Measure 2 above for the safety outcome that includes the whole study duration from entry to week 72. |
| Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits | Weeks (W) 4, 8, 12 | Undetectable HCV RNA was defined as below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0. |
Countries
Puerto Rico, United States
Participant flow
Recruitment details
Participants were enrolled from May 2012 to December 2013 at 42 U.S. sites.
Participants by arm
| Arm | Count |
|---|---|
| HCV Treatment-Naive (Group A) Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV). Among non-cirrhotics, the week 8 serum HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV. | 135 |
| HCV Treatment-Experienced (Group B) Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV. | 122 |
| Total | 257 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 0 | 3 |
| Overall Study | Alternate HCV treatment | 7 | 8 |
| Overall Study | Death | 1 | 1 |
| Overall Study | Ineligible | 0 | 5 |
| Overall Study | Lost to Follow-up | 12 | 6 |
| Overall Study | Non-adherence to study requirements | 4 | 7 |
| Overall Study | Nurse error | 1 | 0 |
| Overall Study | Site closure | 22 | 14 |
| Overall Study | Withdrawal by Subject | 7 | 5 |
Baseline characteristics
| Characteristic | HCV Treatment-Experienced (Group B) | HCV Treatment-Naive (Group A) | Total |
|---|---|---|---|
| Age, Continuous | 53 years | 51 years | 52 years |
| ART Regimen at Entry ATV/RTV + 2 NRTIs | 10 participants | 18 participants | 28 participants |
| ART Regimen at Entry DRV/RTV + 2 NRTIs | 6 participants | 6 participants | 12 participants |
| ART Regimen at Entry EFV + 2 NRTIs | 51 participants | 58 participants | 109 participants |
| ART Regimen at Entry LPV/RTV + 2 NRTIs | 4 participants | 4 participants | 8 participants |
| ART Regimen at Entry Not on ART | 6 participants | 2 participants | 8 participants |
| ART Regimen at Entry RAL + 2 NRTIs | 45 participants | 47 participants | 92 participants |
| CD4 Cell Count at Entry | 622 cells/mm^3 | 646 cells/mm^3 | 625 cells/mm^3 |
| Cirrhosis Status at Screening Cirrhotic | 38 participants | 18 participants | 56 participants |
| Cirrhosis Status at Screening Non-cirrhotic | 84 participants | 117 participants | 201 participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 28 Participants | 17 Participants | 45 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 93 Participants | 117 Participants | 210 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 2 Participants |
| HCV RNA at Entry | 6.9 log10 IU/mL | 6.7 log10 IU/mL | 6.8 log10 IU/mL |
| HIV-1 RNA Quantitation at Entry Quantifiable | 9 participants | 0 participants | 9 participants |
| HIV-1 RNA Quantitation at Entry Unknown | 0 participants | 2 participants | 2 participants |
| HIV-1 RNA Quantitation at Entry Unquantifiable | 113 participants | 133 participants | 246 participants |
| Intravenous Drug Use History Never | 70 participants | 71 participants | 141 participants |
| Intravenous Drug Use History Previously | 52 participants | 64 participants | 116 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 53 Participants | 73 Participants | 126 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 2 Participants | 4 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 5 Participants | 1 Participants | 6 Participants |
| Race (NIH/OMB) White | 58 Participants | 57 Participants | 115 Participants |
| Region of Enrollment United States | 122 participants | 135 participants | 257 participants |
| Sex: Female, Male Female | 29 Participants | 25 Participants | 54 Participants |
| Sex: Female, Male Male | 93 Participants | 110 Participants | 203 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 135 / 135 | 120 / 122 |
| serious Total, serious adverse events | 32 / 135 | 31 / 122 |
Outcome results
Primary
Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24)
SVR24 was defined as undetectable HCV RNA (below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0) at 24 weeks after treatment discontinuation. Participants without HCV RNA for SVR24 determination were considered not to have achieved SVR24.
Time frame: 24 weeks after treatment discontinuation
Population: All eligible participants enrolled (Group B participants who were found ineligible after enrollment, n=5, were excluded).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HCV Treatment-Naive (Group A) | Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) | 34.8 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24) | 25.4 percentage of participants |
Secondary
CD4+ T-Cell Count (CD4) Change From Baseline
Change in CD4 T-cell count was calculated as value at the post entry visit minus the value at entry.
Time frame: Entry and weeks (W) 8, 12, 24, 28, 40, 48, 52, 60, 72
Population: All eligible participants enrolled with CD4 result available from entry and the respective post-entry visit (numbers of participants in Category Titles below; n). Participants who discontinued treatment early due to HCV virologic failure, safety or any other reason started following a separate visit schedule and are not included here.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| HCV Treatment-Naive (Group A) | CD4+ T-Cell Count (CD4) Change From Baseline | W12 CD4 change (A: n=106, B: n=95) | -194 cells/mm^3 |
| HCV Treatment-Naive (Group A) | CD4+ T-Cell Count (CD4) Change From Baseline | W48 CD4 change (A: n=22, B: n=35) | -220 cells/mm^3 |
| HCV Treatment-Naive (Group A) | CD4+ T-Cell Count (CD4) Change From Baseline | W28 CD4 change (A: n=53, B: n=44) | -304 cells/mm^3 |
| HCV Treatment-Naive (Group A) | CD4+ T-Cell Count (CD4) Change From Baseline | W52 CD4 change (A: n=23, B: n=0) | -24 cells/mm^3 |
| HCV Treatment-Naive (Group A) | CD4+ T-Cell Count (CD4) Change From Baseline | W24 CD4 change (A: n=61, B: n=52) | -277 cells/mm^3 |
| HCV Treatment-Naive (Group A) | CD4+ T-Cell Count (CD4) Change From Baseline | W60 CD4 change (A: n=39, B: n=36) | -34 cells/mm^3 |
| HCV Treatment-Naive (Group A) | CD4+ T-Cell Count (CD4) Change From Baseline | W40 CD4 change (A: n=50, B: n=37) | -128 cells/mm^3 |
| HCV Treatment-Naive (Group A) | CD4+ T-Cell Count (CD4) Change From Baseline | W72 CD4 change (A: n=33, B: n=27) | 8 cells/mm^3 |
| HCV Treatment-Naive (Group A) | CD4+ T-Cell Count (CD4) Change From Baseline | W8 CD4 change (A: n=115, B: n=101) | -174 cells/mm^3 |
| HCV Treatment-Experienced (Group B) | CD4+ T-Cell Count (CD4) Change From Baseline | W72 CD4 change (A: n=33, B: n=27) | -15 cells/mm^3 |
| HCV Treatment-Experienced (Group B) | CD4+ T-Cell Count (CD4) Change From Baseline | W8 CD4 change (A: n=115, B: n=101) | -170 cells/mm^3 |
| HCV Treatment-Experienced (Group B) | CD4+ T-Cell Count (CD4) Change From Baseline | W12 CD4 change (A: n=106, B: n=95) | -202 cells/mm^3 |
| HCV Treatment-Experienced (Group B) | CD4+ T-Cell Count (CD4) Change From Baseline | W24 CD4 change (A: n=61, B: n=52) | -263 cells/mm^3 |
| HCV Treatment-Experienced (Group B) | CD4+ T-Cell Count (CD4) Change From Baseline | W28 CD4 change (A: n=53, B: n=44) | -284 cells/mm^3 |
| HCV Treatment-Experienced (Group B) | CD4+ T-Cell Count (CD4) Change From Baseline | W40 CD4 change (A: n=50, B: n=37) | -276 cells/mm^3 |
| HCV Treatment-Experienced (Group B) | CD4+ T-Cell Count (CD4) Change From Baseline | W48 CD4 change (A: n=22, B: n=35) | -237 cells/mm^3 |
| HCV Treatment-Experienced (Group B) | CD4+ T-Cell Count (CD4) Change From Baseline | W52 CD4 change (A: n=23, B: n=0) | NA cells/mm^3 |
| HCV Treatment-Experienced (Group B) | CD4+ T-Cell Count (CD4) Change From Baseline | W60 CD4 change (A: n=39, B: n=36) | -79 cells/mm^3 |
Secondary
Number of Participants With Grade 2 or Higher Signs and Symptoms and Laboratory Abnormalities and Other Serious AEs
This outcome measure was intended for a potential interim analysis when study data up to Week 28 were complete. However, this interim analysis was not conducted. Refer to Outcome Measure 2 above for the safety outcome that includes the whole study duration from entry to week 72.
Time frame: From study treatment dispensation to Week 28
Population: This outcome measure was intended for a potential interim analysis which was not conducted.
Secondary
Number of Participants With Undetectable HCV RNA at Week 16, 20, 24 and 28 Study Visits
Undetectable HCV RNA was defined as below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0. This outcome measure was intended for a potential interim analysis when study data up to Week 28 were complete. However, this interim analysis was not conducted.
Time frame: Weeks (W) 16, 20, 24, and 28
Population: This outcome measure was intended for a potential interim analysis which was not conducted.
Secondary
Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits
Undetectable HCV RNA was defined as below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0.
Time frame: Weeks (W) 4, 8, 12
Population: All eligible participants with HCV RNA result available at the respective visit (numbers of participants in Category Titles below; n). Participants who discontinued treatment early due to HCV virologic failure, safety or any other reason started following a separate visit schedule and are not included here.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HCV Treatment-Naive (Group A) | Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits | W4 HCV RNA (A: n=122, B: n=116) | 9 participants |
| HCV Treatment-Naive (Group A) | Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits | W8 HCV RNA (A: n=117, B: n=104) | 48 participants |
| HCV Treatment-Naive (Group A) | Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits | W12 HCV RNA (A: n=109, B: n=99) | 68 participants |
| HCV Treatment-Experienced (Group B) | Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits | W4 HCV RNA (A: n=122, B: n=116) | 3 participants |
| HCV Treatment-Experienced (Group B) | Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits | W8 HCV RNA (A: n=117, B: n=104) | 28 participants |
| HCV Treatment-Experienced (Group B) | Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits | W12 HCV RNA (A: n=109, B: n=99) | 43 participants |
Secondary
Percentage of Participants With Grade 3 or Higher Adverse Events (AEs)
Number of participants who experienced an AE (sign or symptom or laboratory abnormality) of Grade 3 or higher at any time after baseline while on study. The AEs were graded by the clinicians according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening.
Time frame: From study treatment dispensation to Week 72
Population: All eligible participants enrolled (Group B participants who were found ineligible after enrollment, n=5, were excluded).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HCV Treatment-Naive (Group A) | Percentage of Participants With Grade 3 or Higher Adverse Events (AEs) | 74.1 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With Grade 3 or Higher Adverse Events (AEs) | 73.8 percentage of participants |
Secondary
Percentage of Participants With HIV-1 Viral Load <50 Copies/mL
HIV-1 RNA testing was performed with Abbott RealTime HIV-1 assay (LLOQ=40 copies/mL) or with Roche COBAS AmpliPrep/Taqman HIV-1 assay (LLOQ=20 copies/mL).
Time frame: Entry and weeks (W) 4, 8, 12, 24, 28, 40, 48, 52, 60, 72
Population: All eligible participants with HIV-1 RNA result available at the respective visit (numbers of participants in Category Titles below; n). Participants who discontinued treatment early due to HCV virologic failure, safety or any other reason started following a separate visit schedule and are not included here.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W28 HIV-1 RNA: (A: n=54, B: n=45) | 98.1 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W4 HIV-1 RNA (A: n=123, B: n=114) | 98.4 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W40 HIV-1 RNA (A: n=52, B: n=38) | 92.3 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W12 HIV-1 RNA (A: n=108, B: n=99) | 98.1 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W48 HIV-1 RNA (A: n=23, B: n=33) | 100.0 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W0 HIV-1 RNA (A: n=133, B: n=122) | 100.0 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W52 HIV-1 RNA (A: n=24, B: n=0) | 100.0 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W24 HIV-1 RNA (A: n=62, B: n=52) | 100.0 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W60 HIV-1 RNA (A: n=40, B: n=36) | 100.0 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W72 HIV-1 RNA (A: n=34, B: n=27) | 97.1 percentage of participants |
| HCV Treatment-Naive (Group A) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W8 HIV-1 RNA (A: n=117, B: n=104) | 100.0 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W72 HIV-1 RNA (A: n=34, B: n=27) | 100.0 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W0 HIV-1 RNA (A: n=133, B: n=122) | 92.6 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W4 HIV-1 RNA (A: n=123, B: n=114) | 96.5 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W8 HIV-1 RNA (A: n=117, B: n=104) | 96.2 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W12 HIV-1 RNA (A: n=108, B: n=99) | 98.0 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W24 HIV-1 RNA (A: n=62, B: n=52) | 100.0 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W28 HIV-1 RNA: (A: n=54, B: n=45) | 100.0 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W40 HIV-1 RNA (A: n=52, B: n=38) | 100.0 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W48 HIV-1 RNA (A: n=23, B: n=33) | 100.0 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W52 HIV-1 RNA (A: n=24, B: n=0) | NA percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With HIV-1 Viral Load <50 Copies/mL | W60 HIV-1 RNA (A: n=40, B: n=36) | 97.2 percentage of participants |
Secondary
Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12)
SVR12 was defined as undetectable HCV RNA (below the lower limit of quantitation of the assay and target not detected by Roche COBAS® TaqMan® HCV Test v2.0) at 12 weeks after treatment discontinuation. Participants without HCV RNA for SVR12 determination were considered not to have achieved SVR12.
Time frame: 12 weeks after treatment discontinuation
Population: All eligible participants enrolled (Group B participants who were found ineligible after enrollment, n=5, were excluded).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HCV Treatment-Naive (Group A) | Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12) | 35.6 percentage of participants |
| HCV Treatment-Experienced (Group B) | Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12) | 30.3 percentage of participants |